Cardiff Oncology, Inc. has announced a KOL webinar scheduled for April 30, 2026, to discuss the promising data from an investigator-initiated trial evaluating the single-agent clinical activity of onvansertib in patients with chronic myelomonocytic leukemia (CMML). The session will feature insights from Dr. Mrinal Patnaik, a leading expert in hematology and precision genomics at the Mayo Clinic, who will provide a detailed analysis of the trial’s findings and their implications for treatment strategies in myeloid neoplasms.

The significance of this development lies in onvansertib’s mechanism as a PLK1 inhibitor, a validated target in oncology that addresses critical treatment gaps in cancers driven by RAS mutations. The ongoing Phase 2 trial for metastatic colorectal cancer (mCRC) highlights the drug’s potential to improve outcomes in a patient population with significant unmet needs. Initial data suggest robust clinical activity, particularly in hard-to-treat tumors, indicating that onvansertib may help overcome treatment resistance and enhance therapeutic efficacy in CMML and other PLK1-driven malignancies.

This webinar represents a pivotal moment for researchers and clinicians focused on myeloid neoplasms, as it may shift current paradigms in treatment approaches. The insights shared could accelerate the integration of PLK1 inhibition into clinical practice and inform future drug development timelines, particularly for therapies targeting the vulnerabilities of tumors in the context of precision medicine. The focus on investigator-initiated trials underscores the importance of collaborative research efforts in advancing innovative cancer therapies.

Source: globenewswire.com